Navigation Links
Alzheimer's Drug Development Summit: CBI to Donate Portion of This Week's Proceeds to the Alzheimer's Association
Date:9/21/2009

WOBURN, Mass., Sept. 21 /PRNewswire/ -- The Center for Business Intelligence (CBI) announced today that they will donate a portion of the proceeds from their Alzheimer's Drug Development Summit to the Alzheimer's Association. CBI will donate $100 for every registration completed this week, September 21-25, 2009, in recognition of World Alzheimer's Day.

World Alzheimer's Day joins Alzheimer's associations, globally, to raise awareness and encourage citizens to take action against the disease. CBI is committed to developing forums that unite industry thought leaders in the field of Alzheimer's research and drug development. "By putting together cutting-edge forums and supporting the Alzheimer's Association, we're proud to be doing our part on this very important day," said Michelle DeMunbrun, Program Manager at CBI. "Every little bit counts, and with all of our collective efforts, it's only a matter of time before we establish a cure for this devastating disease."

The annual Alzheimer's Summit, in its third year, will be chaired by Ronald Black, M.D., Assistant Vice President, Neuroscience, Wyeth. The conference will take place in Arlington, VA, on December 8-9, 2009. Day-two case study, "Addressing the Two Most Challenging Aspects of Alzheimer's Clinical Trials -- Accelerating Patient Recruitment and Reducing Drop-Out Rates" will be a highlight at this timely and pertinent event. In addition to five other case studies and an extended panel discussion, attendees will have multiple opportunities to network with industry colleagues.

Top neuroscience and drug development executives from companies such as Eisai, Alzheimer's Association, The Critical Path Institute, Elan Pharmaceuticals, Eli Lilly, GlaxoSmithKline, Wyeth and The National Institute on Aging will explore how to:

  • Examine targeting protein kinases and the unique challenges associated with CNS drug discovery
  • Discuss whether disease modifying therapeutics can show symptomatic benefits
  • Assess whether the AD drug candidates, to date, failed the clinical trials or the clinical trials failed the drugs
  • Gain a better understanding of AB trafficking and the peripheral sink hypothesis
  • Learn the potential role of MRI and PET imaging in biomarkers in facilitating Alzheimer's disease drug development
  • Examine the implications of ADNI data for use of neuroimaging and fluid biomarkers in clinical trials for Alzheimer's disease
  • Discuss the integration of a mobile clinical network into an Alzheimer's clinical trial to meet sponsor and investigator deliverables and objectives

The conference brings together key researchers and stakeholders to examine the latest symptomatic and disease modifying approaches for the clinical development of new AD therapies. For more information on the conference or to view the agenda, please visit http://www.cbinet.com/alzheimers.

About CBI:

A subsidiary of Advanstar Communications, The Center for Business Intelligence is dedicated to developing market-driven, unbiased conferences in the pharmaceutical, biotechnology, and medical device industries. For more information, please visit http://www.cbinet.com.

For additional information or media inquiries, please contact: Emily Forest, Marketing Manager, at 339-298-2156.

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE The Center for Business Intelligence
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Allegiance Equity Corporation announces collaboration with Canadian Dairy Commission and Guelph Food Technologies Corporation for Alzheimers and Dementia formulation GG-XT
2. Diagenic Partners With DNAVision to Offer First Breast Cancer and Alzheimers Gene-Expression Blood Tests
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
5. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
6. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
7. Global Experts Explore Entire Spectrum of Aids Vaccine Development
8. Vical Names Andrew de Guttadauro Vice President, Corporate Development
9. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
10. SemBioSys updates Apo AI development program
11. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... , Feb. 24, 2017  OncoSec Medical Incorporated ("OncoSec") ... will host a Key Opinion Leader event to highlight ... oral and poster presentation at the upcoming 2017 ASCO-SITC ... KOL event will be held in-person and via live ... / 9:00 AM PST at the Lotte New York ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... portfolio to include an array of biochemical analyses critical for Lead Discovery. ... drive their hit-to-lead and SAR programs, including inhibitor potency and selectivity, mechanism of ...
(Date:2/23/2017)... ATLANTA , Feb. 23, 2017  In Atlanta, it ... art, fashion, and culture intertwine to create an expressive and ... often reflect this energy and contribute to it. ... , Hair Fairies seeks to carry on that ... The Atlanta salon is the newest ...
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... ... (FDA) de novo clearance to begin marketing the SPEAC® System, the Brain Sentinel® ... adults at home or in healthcare facilities during periods of rest. A lightweight, ...
Breaking Biology Technology:
(Date:1/30/2017)... 30, 2017   Invitae Corporation (NYSE: ... information companies, today announced that it will report its ... 2017 guidance on Monday, February 13, 2017, and Invitae,s ... at 4:45 p.m. Eastern / 1:45 p.m. Pacific. ... briefly review financial results, guidance, and recent developments and ...
(Date:1/26/2017)... , Jan. 26, 2017  Acuity Market ... for Biometrics and Digital Identity".  Acuity characterizes 2017 ... identity when increased adoption reflects a new understanding ... "Biometrics and digital identity are often ... Maxine Most , Principal of Acuity Market ...
(Date:1/24/2017)... Jan. 24, 2017 Biopharm Reports has ... laboratory use of nuclear magnetic resonance spectroscopy (NMR). ... and profiled current practices, developments, trends and end-user ... as growth and opportunities. These areas include growth ... instruments, needs and innovation requirements, hyphenated NMR techniques, ...
Breaking Biology News(10 mins):